Business, energy, technology, markets and global industry news from Business News Today

minimal residual disease

PharmaDeviceNews minimal residual disease
Circulating tumor DNA testing can reveal molecular traces of residual cancer after apparently curative treatment, but the key clinical question is whether acting on that earlier signal can ultimately improve survival. Representative image.
Features & Analysis

Can a blood test find cancer relapse before a scan? What ctDNA MRD can and cannot tell clinicians

Circulating tumor DNA can detect molecular traces of residual cancer after apparently curative treatment, but proving that acting on an earlier signal improves survival is the harder challenge.

Read More
Representative image of clinical biomarker analysis in a modern research laboratory, highlighting how drug developers are working to turn biological signals into regulator-accepted surrogate endpoints for faster, evidence-based clinical trials.
Features & Analysis

Why clinical biomarkers face a slow climb before regulators accept them as surrogate endpoints

Biomarkers can speed drug approvals, but weak validation can haunt sponsors. FDA and EMA are tightening the path from signal to endpoint.

Read More
Medical Devices & Diagnostics

Can ultrasensitive ctDNA monitoring reshape how clinicians track neoadjuvant breast cancer therapy response?

New PREDICT-DNA data suggests ultrasensitive ctDNA monitoring may outperform traditional markers in breast cancer relapse prediction. Read the full analysis.

Read More